---
title: "InMed Reports Q3 FY2026: Net Loss $3.0M, Cash $5.2M, INM-901 shows human organoid anti‑inflammatory effects"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285525494.md"
description: "InMed Pharmaceuticals reported a Q3 FY2026 net loss of $3.0 million, an increase from $2.1 million year-over-year, attributed to higher R&D and financing costs. The company has $5.2 million in cash and short-term investments, down from $10.8 million in June 2025. INM-901 demonstrated anti-neuroinflammatory effects in human 3D brain organoids, showing promise for future applications. Additionally, BayMedica's commercial operations are being discontinued, with a wind-down expected by June 30, 2026."
datetime: "2026-05-07T10:03:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285525494.md)
  - [en](https://longbridge.com/en/news/285525494.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285525494.md)
---

# InMed Reports Q3 FY2026: Net Loss $3.0M, Cash $5.2M, INM-901 shows human organoid anti‑inflammatory effects

**InMed reported a Q3 fiscal 2026 net loss of $3.0 million and cash, cash equivalents and short‑term investments of $5.2 million while INM-901 showed anti‑neuroinflammatory effects in human 3D brain organoids.**

**Key Highlights:**

-   Q3 (ended Mar 31, 2026) net loss of $3.0M vs $2.1M year‑ago; increase driven by higher R&D and financing costs.
-   Cash, cash equivalents and short‑term investments totaled $5.2M as of Mar 31, 2026 (down from $10.8M on Jun 30, 2025).
-   INM-901 preclinical data in two human 3D brain organoid models showed dose‑dependent reductions in IL‑6 and IL‑8.
-   Anti‑inflammatory effects of INM-901 are consistent with prior in vivo and ex vivo findings, supporting translational potential.
-   BayMedica commercial operations classified as discontinued; wind down expected substantially complete by June 30, 2026.

Original SEC Filing: InMed Pharmaceuticals Inc. \[ INM \] - 8-K - May. 06, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [INM.US](https://longbridge.com/en/quote/INM.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)

## Related News & Research

- [Full Transcript: Cellectar Biosciences Q1 2026 Earnings Call](https://longbridge.com/en/news/286422585.md)
- [Eton Pharmaceuticals Q1 product sales rise driven by portfolio expansion](https://longbridge.com/en/news/286461579.md)
- [Co-Diagnostics Advances Ebola Preparedness With New Bundibugyo Virus Assay Strategy; Stock Up](https://longbridge.com/en/news/286956797.md)
- [08:00 ETAvance Clinical Receives Frost & Sullivan's 2026 Global Company of the Year Recognition for Excellence in Biotech CRO Leadership](https://longbridge.com/en/news/286094661.md)
- [Tiziana Announces New Positive Clinical Data For Intranasal Foralumab In Non-Active Secondary Progressive Multiple Sclerosis](https://longbridge.com/en/news/286899753.md)